Abstract：Objective To investigate the features and duration of viral nucleic acid shedding in children with influenza A. Methods The clinical data of 90 children with influenza A with positive influenza A virus nucleic acid in nasopharyngeal swab detected by PCR were collected, and these children were divided into simple influenza A group (n=10), influenza A-pneumonia group (n=61), influenza A-nervous system damage group (n=10), and influenza A-underlying disease group (n=9). A retrospective analysis was performed for clinical features, treatment process, duration of viral nucleic acid shedding, and prognosis. Results The most common symptoms in these children were fever (89/90, 99%), cough (89/90, 99%), running nose (69/90, 77%), shortness of breath (26/90, 29%), and myalgia (23/90, 26%). The mean duration of viral nucleic acid shedding in 90 children was 9.4±2.9 days. The simple influenza A group had a significantly shorter duration of viral nucleic acid shedding than the influenza A-pneumonia, influenza A-nervous system damage, and influenza A-underlying disease groups (P < 0.05), while there were no significant differences between the influenza A-pneumonia, influenza A-nervous system damage, and influenza A-underlying disease groups (P > 0.05). The children who received antiviral therapy within 48 hours after disease onset had significantly shorter duration of viral nucleic acid shedding and time to body temperature recovery than those who received antiviral therapy more than 48 hours after disease onset (P < 0.05). Of all the children with body temperature recovery, 83% still tested positive for viral nucleic acid. Conclusions Complications, underlying diseases, and timing of antiviral therapy are influencing factors for the duration of influenza A virus nucleic acid shedding, and whether body temperature returns to normal cannot be used to decide whether to continue antiviral therapy.
ZHOU Gao-Feng,WANG Hong-Mei,ZHANG Rui-Mu et al. Influencing factors for duration of viral nucleic acid shedding in children with influenza A[J]. CJCP, 2016, 18(12): 1269-1271.
Mu YP, Zhang ZY, Chen XR, et al. Clinical features, treatments and prognosis of the initial cases of pandemic influenza HINI 2009 virus infection in Shanghai China[J]. QJM, 2010, 103(5):31l-317.
Cheng PK, To AP, Leung TW, et al. Oseltamivir-and amantadine-resistant influenza virses A (H1N1)[J]. Emerg Infect Dis, 2010, 16(1):155-156.
[9]
Smith JR, Ariano RE, Toovey S. The use of antiviral agents for the management of severe influenza[J]. Crit Care Med, 2010, 38(4 Supp1):e43-e51.
[10]
Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009[J]. N Engl J Med, 2009, 361(20):1935-1944.
